CanChew Rx (cannabidiol chewing gum) / Axim Biotech - LARVOL DELTA

Axim Biotechnologies completes first phase of pharmacokinetic clinical study on cannabinoid-based gum with dronabinol (GlobeNewswire) - "AXIM Biotechnologies...announced today that it has completed the first phase of its pharmacokinetic clinical study on its cannabinoid-based chewing gum with dronabinol, a synthetic form of tetrahydrocannabinol (THC). The multi-phase study is aimed to understand how cannabis may serve as a treatment for chemotherapy-related symptoms."

Trial primary completion date • CNS Disorders

Effects of Cannabidiol Chewing Gum on Perceived Pain and Well-Being of Irritable Bowel Syndrome Patients: A Placebo-Controlled Crossover Exploratory Intervention Study with Symptom-Driven Dosing. (PubMed, Cannabis Cannabinoid Res) - "The low use of the gums also indicates that the benefits experienced by these patients generally did not outweigh practical disadvantages such as prolonged chewing throughout the day. The very high intra- and inter-individual variation in IBS symptoms warrant future trials that are more personalized, for example by applying an N-of-1 (rotating) design with individualized dose titration."

Clinical • Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Pain